Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanophilin is a Rab effector protein that acts as a molecular adaptor facilitating the transport of melanosomes, pigment-containing organelles, within melanocytes. It forms a tripartite complex with the small GTPase Rab27a and the actin-based motor protein myosin Va, linking melanosomes to the actin cytoskeleton to enable their movement to the cell periphery and subsequent transfer to keratinocytes. Disruption of Melanophilin, particularly due to mutations in the MLPH gene, impairs this transport process, leading to abnormal melanosome distribution and loss of normal pigmentation, as seen in Griscelli syndrome type 3. Melanophilin contains several distinct domains: a conserved N-terminal Rab27-binding domain (R27BD), a medial myosin Va-binding domain (MBD), and a C-terminal actin-binding domain (ABD). Its principal biological role is in pigmentation by regulating melanosome trafficking and distribution in pigment-producing cells[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melanophilin (MLPH).